S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NASDAQ:LIXT

Lixte Biotechnology (LIXT) Stock Forecast, Price & News

$1.95
+0.20 (+11.43%)
(As of 09/20/2023 ET)
Compare
Today's Range
$1.81
▼
$2.25
50-Day Range
$1.75
▼
$7.53
52-Week Range
$1.58
▼
$27.00
Volume
198,032 shs
Average Volume
21,434 shs
Market Capitalization
$4.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

LIXT stock logo

About Lixte Biotechnology (NASDAQ:LIXT) Stock

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

LIXT Price History

LIXT Stock News Headlines

August 27, 2023 | wsj.com
Lixte Biotechnology Holdings Inc. Wt
July 20, 2023 | finance.yahoo.com
LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
September 21, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
July 18, 2023 | benzinga.com
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 18, 2023 | msn.com
LIXTE Biotechnology falls after company launches $3.5M registered direct offering of shares
July 18, 2023 | marketwatch.com
Lixte Bio Shares Tumble 31% After Pricing $3.5M Stock Offering
July 18, 2023 | finance.yahoo.com
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
July 17, 2023 | marketwatch.com
Lixte Biotechnology Shares Rise 25% on LB-100 Cancer Treatment Research
September 21, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
July 17, 2023 | msn.com
What's Going On With Lixte Biotechnology (LIXT) Stock?
July 17, 2023 | finance.yahoo.com
Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
June 23, 2023 | finance.yahoo.com
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
June 7, 2023 | finance.yahoo.com
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
June 5, 2023 | finance.yahoo.com
Owning 53% in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) means that insiders are heavily invested in the company's future
June 2, 2023 | msn.com
LIXTE Biotechnology Holdings announces reverse stock split to obtain minimum price compliance
June 2, 2023 | marketwatch.com
Lixte Biotech Shares Down 8% After Company Announces Reverse Stock Split
June 2, 2023 | finance.yahoo.com
LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023
May 30, 2023 | finance.yahoo.com
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
May 12, 2023 | marketwatch.com
8-K: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
April 28, 2023 | marketwatch.com
Global Neurometabolic Disorders Market Share 2023-2030 with On-going Demand Status
April 24, 2023 | finance.yahoo.com
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
April 4, 2023 | finance.yahoo.com
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
March 24, 2023 | marketwatch.com
Gaucher Disease Drugs Market Top Players By 2031
March 21, 2023 | marketwatch.com
Protein Phosphatase 2A Market Top Players and Forecast till 2028
February 21, 2023 | marketwatch.com
Gaucher Disease Drugs Market Massive Growth Strikes Due To Technological Innovation During 2023-2028
February 14, 2023 | finance.yahoo.com
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH
February 13, 2023 | finance.yahoo.com
Lixte Biotechnology Holdings, Inc. (LIXTW)
See More Headlines
Receive LIXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

LIXT Company Calendar

Last Earnings
8/09/2023
Today
9/20/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LIXT
CUSIP
N/A
CIK
1335105
Web
www.lixte.com
Phone
(631) 830-7092
Fax
631-982-5050
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,310,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-565.06%
Return on Assets
-124.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.68
Quick Ratio
7.68

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.00 per share
Price / Book
1.95

Miscellaneous

Outstanding Shares
2,249,000
Free Float
1,840,000
Market Cap
$4.39 million
Optionable
Not Optionable
Beta
-0.49
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. John S. Kovach M.D. (Age 86)
    Founder, Pres, CEO, Chief Scientific Officer & Chairman
    Comp: $250k
  • Mr. Robert Neal Weingarten (Age 71)
    VP & CFO
    Comp: $175k
  • Mr. Eric J. Forman J.D. (Age 44)
    VP & COO
    Comp: $178.82k
  • Dr. James S. Miser M.D. (Age 76)
    Chief Medical Officer
    Comp: $175k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













LIXT Stock - Frequently Asked Questions

How have LIXT shares performed in 2023?

Lixte Biotechnology's stock was trading at $5.09 at the beginning of the year. Since then, LIXT stock has decreased by 61.7% and is now trading at $1.95.
View the best growth stocks for 2023 here.

Are investors shorting Lixte Biotechnology?

Lixte Biotechnology saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 7,200 shares, a drop of 44.2% from the August 15th total of 12,900 shares. Based on an average daily volume of 133,800 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the company's stock are sold short.
View Lixte Biotechnology's Short Interest.

When is Lixte Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our LIXT earnings forecast.

How were Lixte Biotechnology's earnings last quarter?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) released its quarterly earnings data on Wednesday, August, 9th. The company reported ($1.00) earnings per share (EPS) for the quarter.

When did Lixte Biotechnology's stock split?

Lixte Biotechnology shares reverse split on Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Lixte Biotechnology IPO?

(LIXT) raised $7 million in an initial public offering (IPO) on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital acted as the underwriters for the IPO.

What is Lixte Biotechnology's stock symbol?

Lixte Biotechnology trades on the NASDAQ under the ticker symbol "LIXT."

Who are Lixte Biotechnology's major shareholders?

Lixte Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.61%). Insiders that own company stock include Eric Forman, Regina Brown and Rene Bernards.
View institutional ownership trends.

How do I buy shares of Lixte Biotechnology?

Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lixte Biotechnology's stock price today?

One share of LIXT stock can currently be purchased for approximately $1.95.

How much money does Lixte Biotechnology make?

Lixte Biotechnology (NASDAQ:LIXT) has a market capitalization of $4.39 million. The company earns $-6,310,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis.

How can I contact Lixte Biotechnology?

Lixte Biotechnology's mailing address is 248 ROUTE 25A NO. 2, EAST SETAUKET NY, 11733. The official website for the company is www.lixte.com. The company can be reached via phone at (631) 830-7092, via email at info@lixte.com, or via fax at 631-982-5050.

This page (NASDAQ:LIXT) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -